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Reassessing the value of vaccines
In May, 1974, WHO launched the Expanded Programme 
on Immunization—the global programme to immunise 
children worldwide with a set of (at the time) six core 
vaccines. 40 years on, the GAVI Alliance has brought 
us together, a group of 29 leading technical experts 
in health and development economics, cognitive 
development, epidemiology, disease burden, and 
economic modelling to review and understand the 
broader outcomes of vaccines beyond morbidity and 
mortality, to identify research opportunities, and 
to create a research agenda that will help to further 
quantify the value of this eﬀ ect.
What is the value of immunising every child with all 
11 vaccines that WHO now recommends,1 beyond the 
prevention of illness and death? The full beneﬁ ts of 
childhood vaccination could reach well into a child’s life, 
through adulthood, into the wider community, and, 
ultimately, the national economy.2 Some evidence of 
these beneﬁ ts has already been generated, but gaps in 
knowledge remain.
For example, preliminary research suggests that a 
5-year improvement in life expectancy can translate 
into 0·3–0·5% more annual growth added to income per 
head.3 Similarly, results of research done in Bangladesh 
show that the beneﬁ ts of antibodies from maternal 
tetanus vaccinations passing from a mother to her 
unborn child can lead to gains of about 0·25 years of 
schooling for children whose parents did not attend 
school.4 And ﬁ ndings from the Philippines showed that 
vaccinations induced improvements in test scores in 
children,5 which had a return on investment as high as 
21% when translated into the earning gains of adults.6
Meanwhile in South Africa, researchers have shown 
a signiﬁ cant association between coverage of measles 
vaccination and the level of school-grade attainment 
in sibling-pairs, after controlling for intrinsic factors 
such as birth order, education levels of parents, and 
household wealth.7 This research suggests that, on 
average, 1 year of schooling is gained for every six 
children vaccinated against measles. But evidence to 
link health inputs and wealth outcomes needs to be 
further assessed and investigated. 
Vaccines are usually given when the rate of brain 
development is at its peak, which can beneﬁ t cognitive 
development through prevention of illness and its 
neurological complications (eg, encephalitis). But 
so far, the only evidence for this model is based on 
observational studies; such studies are an important ﬁ rst 
step, but more work is needed. Similarly, evidence for 
the positive links between vaccines and the educational 
attainment of children, or how improvements in child 
survival can lead to lower fertility rates, exists but needs 
more elaboration. And although it seems obvious that 
repeated infections would have a synergistic negative 
eﬀ ect, infections are still assessed in isolation. 
Similarly, there is evidence for links between 
improvements in survival, cognition, physical capacity, 
and educational attainment, and increases in workforce 
supply and productivity.8 How reductions in mortality 
and morbidity can boost consumption and gross 
domestic product (GDP) can be modelled, but to 
understand these links better, more research is needed.
Although it follows logically that vaccination can 
prevent disease and therefore reduce health-care 
costs, more evidence is needed. This is also the case for 
evidence that links loss of productivity with speciﬁ c 
diseases. We have some evidence, but the picture 
remains incomplete. Follow-up studies for education 
and income are needed. For expediency, these 
studies could be done through follow-up of previous 
randomised controlled trials and through investigators 
ﬁ nding clever ways to add these questions onto 
prospective studies, such as studies embedded in health 
and demographic surveillance sites.
As well as generating new data, it is important 
to obtain and mine data from previous studies of 
existing vaccines used in the Expanded Programme on 
Immunization. Similarly, the links between productivity 
and speciﬁ c diseases could be made clearer through 
the addition of economic or other quantitative 
socioeconomic analyses to clinical trials of new vaccines, 
such as those against dengue and malaria. Also, the 
need for diﬀ erent metrics to measure the eﬀ ectiveness 
of vaccines could be met by the use of economic 
approaches that include broader measures of wellbeing, 
such as willingness to pay and value of statistical life.2 
These measures are by no means perfect and are not 
straightforward to interpret when applied to childhood 
vaccination. One of the diﬃ  culties in interpretation 
is that it can be problematic to separate the eﬀ ect of 
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vaccinations from other health-care interventions 
during assessment of costs and beneﬁ ts. 
Clearly, a lot of work still needs to be done, but the 
potential rewards are huge. Two studies have already 
been commissioned by GAVI to try to ﬁ ll these gaps—
one in Nigeria will explore issues of equity and trust 
(these issues can play a part in the overall eﬀ ect and 
coverage of vaccines); the other will look for new 
evidence of economic beneﬁ ts with vaccination in 
India. However, GAVI is not a research organisation. 
The main drive must come from the broader academic 
community and not simply organisations traditionally 
concerned with vaccines. 
Mortality reduction is already reason enough to have 
every child on this planet fully immunised, as shown by 
the Millennium Development Goals and the post-2015 
development agenda. Now this ﬁ ght is not simply about 
saving lives, but about maximising the full lifetime 
potential of these children and the economic health of 
the families and countries in which they live. 
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